Fig. 2: Pre- and post-treatment direct cytotoxicity, ADCC and SNP status. | British Journal of Cancer

Fig. 2: Pre- and post-treatment direct cytotoxicity, ADCC and SNP status.

From: Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy

Fig. 2

a Direct cytotoxicity levels elicited against K562 cells by patient PBMCs pre- (n = 40) and post-treatment (n = 25). The K562 dataset lost a pre-treatment sample due to a technical issue acquiring the sample. b Direct cytotoxicity and trastuzumab-mediated ADCC levels elicited against SKBR3 cells by patient PBMCs pre- (n = 41) and post-treatment (n = 25). An optimal pooled t test was used to determine statistical significance; all p values were adjusted for multiple testing, *p < 0.05, **p < 0.01, NS not significant. c FCGR SNP frequency and association with pCR in ICORG 10-05 patients. Data covers 37 pre-treatment samples and 24 post-treatment samples from (a) and (b). H histidine, R arginine, I isoleucine, T threonine, Q glutamine, D aspartic acid, N asparagine, V valine, F phenylalanine. Fisher’s Exact test, significant if p < 0.05, NA not available.

Back to article page